行情

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

11.03
+0.38
+3.57%
盘后: 11.03 0 0.00% 16:44 05/16 EDT
开盘
10.59
昨收
10.65
最高
11.38
最低
10.38
成交量
37.10万
成交额
0
52周最高
24.00
52周最低
9.26
市值
7.34亿
市盈率(TTM)
-8.1109
分时
5日
1月
3月
1年
5年
Recap: Aclaris Therapeutics Q1 Earnings
  Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 6天前
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6天前
Aclaris Therapeutics Q1 EPS $(0.31) Up From $(0.57) YoY, Sales $1.45M Down From $1.78M YoY
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.31) per share. This is a 45.61 percent increase over losses of $(0.57) per share from the same period last year. The company reported $1.45 million in
Benzinga · 6天前
BRIEF-Aclaris Therapeutics Reports First Quarter 2022 Financial Results And Provides A Corporate Update
reuters.com · 6天前
Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09, revenue of $1.45M misses by $0.22M
Aclaris Therapeutics press release (NASDAQ:ACRS): Q1 GAAP EPS of -$0.31 beats by $0.09. Revenue of $1.45M (-18.5% Y/Y) misses by $0.22M.
Seekingalpha · 6天前
-- Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q1 Revenue $1.5M
MT Newswires · 6天前
Notable earnings before Tuesday's open
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS,
Seekingalpha · 05/09 15:06
Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates
Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 23:35
更多
暂无数据
了解ACRS最新的财务预测,通过ACRS每股收益,每股净资产,每股现金流等数据分析Aclaris Therapeutics Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

50.00%强力推荐
50.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ACRS价格均价为34.80,最高价位50.00,最低价为26.00。
最高50.00
均价34.80
最低26.00
现价11.03
EPS
实际EPS
预期EPS
-0.32-0.24-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 174
机构持股: 6,415.96万
持股比例: 103.92%
总股本: 6,658.19万
类型机构数股数
增持
49
386.54万
建仓
30
186.74万
减持
37
281.92万
平仓
18
363.58万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.23%
制药与医学研究
+1.02%
高管信息
Non-Executive Chairman/Independent Director
Christopher Molineaux
President/Chief Executive Officer/Co-Founder/Director
Neal Walker
Co-Founder/Chief Financial Officer/Secretary
Frank Ruffo
Chief Scientific Officer
Joseph Monahan
Other
James Loerop
Independent Director
Maxine Gowen
Independent Director
William Humphries
Independent Director
Anand Mehra
Independent Director
Vincent Milano
Independent Director
Andrew Powell
Independent Director
Bryan Reasons
Independent Director
Andrew Schiff
暂无数据
暂无数据
ACRS 简况
Aclaris Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于开发免疫炎症性疾病的候选药物。其候选药物包括ATI-450、ATI-1777、ATI-2138和Undisclosed-Gut Restricted Program。其ATI-450是一种研究用的口服药、小分子选择性丝裂原活化蛋白激酶活化蛋白激酶2或MK2抑制剂化合物,用于治疗类风湿性关节炎。其ATI-1777是一种研究性局部用JAK抑制剂化合物,用于治疗特应性皮炎。其ATI-2138是一种研究性口服ITK/TXK/JAK3或ITJ抑制剂化合物,用于治疗银屑病和/或炎症性肠病,这两种疾病都是T细胞介导的自身免疫疾病。

微牛提供Aclaris Therapeutics Inc(NASDAQ-ACRS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ACRS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ACRS股票基本功能。